Response rates were:
(1) bacteremic patients,60%;
(a) single gram-positive patients,57%;
(b) single gram-negative patients, 55%;
(c) polymicrobial patients, 100%; and
(2) non-bacteremic patients, 50%.
Ceftriaxone plus amikacin was effective in 135/183 (74%) patients with a median time defervescence of 3 days (1-11). 70% of subjects with a PMN cell count/mm3 <100 responded to the therapy, and 77% of those subjects with a PMN cell count/mm3 100-500 also responded to the therapy.
Note: The initial antibiotic regimen was discontinued due to side-effects (cutaneous eruption allergic reactions) experienced by 3 patients.